FDA Orders Drug Interaction Studies on Potassium-Lowering Kayexalate

Generic Line
The FDA is requiring Concordia Pharmaceuticals to conduct drug interaction studies with its potassium-lowering drug Kayexalate, after the agency’s review of just-approved Veltassa showed that the drug bound to about half of the oral medications tested.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00